In a report issued on December 6, Sean Lavin from BTIG maintained a Hold rating on Edwards Lifesciences (EW). The company’s shares closed on Friday at $157.21.
Lavin said:
“Day reaffirmed our optimistic view on the TAVR and mitral opportunities. After interacting with docs, viewing demos, and assessing the post COAPT landscape, we believe EW may be closer to a true transseptal mitral replacement product than we previously thought though this is still years away. EW’s mitral/tricuspid portfolio remains the most well rounded and today’s update was a positive. M3 has been in at least 30 patients and EVOQUE has been successfully implanted. EW also has multiple catheter and MIS surgical repair options. On TAVR, there were relatively less exciting LT drivers but we appreciate progress on early TAVR. At least some docs are believers in treating before symptoms and this view could garner support with data.”
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 9.0% and a 56.6% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings Inc, Helius Medical Technologies, and Tactile Systems Technology.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Edwards Lifesciences with a $169.07 average price target.
See today’s analyst top recommended stocks >>
Edwards Lifesciences’ market cap is currently $32.87B and has a P/E ratio of 47.21. The company has a Price to Book ratio of 9.78.
Based on the recent corporate insider activity of 114 insiders, corporate insider sentiment is negative on the stock. Last month, Robert Sellers, the VP, Corp. Contr of EW sold 7,859 shares for a total of $1,203,631.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. It operates through the following geographical segments: United States, Europe, Japan, and Rest of the World. Its products are categorized into three areas: Surgical Heart Valve Therapy, Transcatheter Heart Valves, and Critical Care.
